SLC5A2 and diabetes mellitus: The Dapagliflozin and Prevention of Adverse Outcomes in Chronic Kidney Disease (DAPA-CKD; ClinicalTrials.gov NCT03036150) and EMPA-KIDNEY studies (NCT03594110) will further assess the renal protective effects of SGLT2 inhibitors in patients with chronic kidney disease (CKD) with or without diabetes.